Evaluation of the Degradation of Renal Function Post Nephrectomy According to Retinal Vascularisation Parameters

NCT ID: NCT04855123

Last Updated: 2024-05-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-18

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic kidney failure in the single remaining kidney is one of the dreaded complications of nephrectomy in patients operated on for cancer-related reasons (1). Indeed, chronic kidney disease (CKD) is associated with major cardiovascular morbidity and mortality (2).

To date, there are few non-invasive methods available to predict the onset and progression of CKD in patients for whom nephrectomy is indicated. Preoperative creatinine and glomerular filtration rate are poor predictors of the subsequent risk of single kidney failure (1). Early predictive markers could help anticipate the management of CKD in patients for whom progression to end-stage renal disease is predictable. Furthermore, such markers could be used as a decision-making aid to specify the type of nephrectomy to be preferred (total versus partial nephrectomy).

The state of microcirculation, particularly retinal, is correlated with the progression of certain conditions such as diabetic nephropathy (3-5). A new technique for evaluating retinal microcirculation called OCT-A (an imaging technique in ophthalmology allowing a precise non-invasive study of the retinal microvascular network) has recently been used by our team to highlight an association between retinal vascularisation and the level of cardiovascular risk in a population of coronary patients without diabetes (6).

We hypothesize that the observation of retinal vascular abnormalities could reflect changes in kidney structure that could underlie chronic renal failure. The aim of this work is thus to evaluate whether the presence of abnormalities in the retinal microvascularisation is 1) predictive of the deterioration in renal function one year after nephrectomy for cancer-related reasons and 2) correlated with renal histological abnormalities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nephrostomy Retinal Vascularisation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient

Group Type OTHER

retinal imaging

Intervention Type OTHER

OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer

paraclinical surveillance

Intervention Type OTHER

blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

retinal imaging

OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer

Intervention Type OTHER

paraclinical surveillance

blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient
* Indication for total nephrectomy for kidney cancer decided with a multidisciplinary oncology consultation
* Kidney scan images available
* Patient affiliated to French national health insurance
* Patient who has given oral consent

Exclusion Criteria

* Pregnant woman
* Ophthalmologic history (macular vascular or degenerative diseases, epiretinal membranes, glaucoma)
* Cannot sit still for 60 minutes
* Metastatic cancer
* Single functional kidney before nephrectomy
* Estimated Glomerular Filtration Flow Rate (CKD-EPI formula) less than 60 mL/min/1.73m2
* Diabetes type 1 or type 2
* Proteinuria at inclusion (or in the 3 months prior to inclusion) on sample with a protein/creatinuria ratio greater than 1g/g or over 24 hours greater than 1g/day
* HIV, HCV or HBV positive serology
* Patient subject to a measure of legal protection (guardianship, curatorship, etc.)


* Patient with increased pressure during the measurement of the intraocular pressure before dilation
* Patient with histological abnormalities suggestive of nephropathy (excluding nephroangiosclerosis) or ischemic parenchymal sequelae of renal vein thrombosis in the pathological analysis of the nephrectomy sample
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chu Dijon Bourgogne

Dijon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mathieu LEGENDRE

Role: CONTACT

03.80.29.37.56 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mathieu LEGENDRE

Role: primary

03.80.29.37.56

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LEGENDRE APJ 2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.